Miro Sciences Ltd (ASX:MSX)
Australia · Delayed Price · Currency is AUD 0.0530
-0.0010 (-1.85%)
At close: Oct 29, 2026
Miro Sciences Company Description
Miro Sciences Ltd engages in the research and development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases.
Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders.
Miro Sciences Ltd was formerly known NeuroScientific Biopharmaceuticals Limited and change its name to Miro Sciences Ltd in October 2026.
The company was incorporated in 2002 and is based in Nedlands, Australia.
Miro Sciences Ltd
| Country | Australia |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Nathan Smith |
Contact Details
Address: Level 1 Nedlands, Washington 6009 Australia | |
| Phone | 61 8 6268 2641 |
| Website | neuroscientific.com |
Stock Details
| Ticker Symbol | MSX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000012973 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nathan Smith | Chief Executive Officer |
| Chris Knee | Chief Financial Officer |